BMS Acquires Autoimmune Portfolio from Novo Nordisk
Bristol-Myers Squibb acquired an exclusive license for Novo Nordisk’s discovery biologics research program.
Bristol-Myers Squibb (BMS) announced on Mar. 24, 2015 that it reached an agreement to acquire an exclusive global license to Novo Nordisk’s discovery biologics research program focused on autoimmune diseases; however, the details of the agreement were not disclosed. The research program is designed to modulate the innate immune system as a therapy for autoimmune diseases.
With the acquisition, BMS expands its immunoscience and immuno-oncology research platform. The company saw success in this area of research earlier in 2015 when one of its late-stage studies for Opdivo (nivolumab) was ended early due to superior overall survival.
Source: Bristol-Myers Squibb
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
